Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agenus Inc.

www.agenusbio.com

Latest From Agenus Inc.

Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts

Gilead will pay $4.9bn to acquire Forty Seven and its potential first-in-class anti-CD47 agent magrolimab. A fast-track development effort in myelodysplastic syndrome will be the initial focus for that asset.

Deals ImmunoOncology

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

Deals Business Strategies

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Liposomes
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Antigenics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Agenus Inc.
  • Senior Management
  • Garo H Armen, PhD, Chmn. & CEO
    Alex Duncan, PhD, CTO
    Julie DeSander, VP, Bus. Dev. & Alliance Mngmt.
    Jennifer Buell, PhD, Pres. & COO
    Christine Klaskin, VP, Fin.
  • Contact Info
  • Agenus Inc.
    Phone: (781) 674-4400
    3 Forbes Rd.
    Lexington, MA 02421-7305
    USA
UsernamePublicRestriction

Register